Relyvrio, a drug meant to treat amyotrophic lateral sclerosis (ALS), failed clinical trials due to not providing significant symptom relief in those suffering from the disease.
In particular, the phase 3 clinical trial showed that the drug, which is a combination of sodium phenylbutyrate and taurursodiol, failed to improve patient symptoms after 48 weeks of treatment. Additionally, compared to a placebo, the medication was unable to significantly improve reported quality of life, overall survival, and respiratory function, CNN Health reported.
